Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07217886 · ClinicalTrials.gov registry record · Phase 1
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
A Phase 1 study of Renal Impairment, sponsored by Shionogi.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT07217886 is a Phase 1 study of Renal Impairment that is actively recruiting participants, run by Shionogi. The registered enrollment target is 40 participants, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (21% higher). The trial reports 4 study locations across 2 states.
The verdict
NCT07217886, a Phase 1 study of Renal Impairment, is actively recruiting participants, sponsored by Shionogi.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or renal impairment requiring hemodialysis (HD), and in participants with normal renal function.
Conditions Studied
Interventions
- DRUG S-892216-PO
Study Locations (4)
Florida
- Orlando Clicinal Research Center - Orlando
- Global Clinical Professionals (GCP) LLC - St. Petersburg
- Genesis Clinical Research - Tampa
Tennessee
- Alliance for Multispecialty Research (AMR)-Knoxville - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2026-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07217886
The ClinicalTrials.gov registry entry for NCT07217886 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (21% higher). The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which S-892216-PO is the first listed.
NCT07217886 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07217886 about?
NCT07217886 is a clinical study titled "A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls". The purpose of this study is to measure the pharmacokinetics, safety, and tolerability of S-892216 (S-892216-PO) in participants with mild, moderate, or severe renal impairment not on dialysis, or renal impairment requiring hemodialysis (HD), and in participants with normal renal function.
What is the current status of trial NCT07217886?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-10-16. Estimated completion is 2026-06-05.
What conditions does trial NCT07217886 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT07217886?
The interventions under investigation include: S-892216-PO (DRUG).
Who is sponsoring clinical trial NCT07217886?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07217886 being conducted?
This trial has 4 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.